BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29

• Press Releases

  LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences

  November 14, 2024

   · 

  2 min read
• 

  Cell Therapy

  Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment

  Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic leukemia after Bristol Myers Squibb’s Breyanzi was approved in the indication earlier this year.

  November 14, 2024

   · 

  1 min read

   · 

  Annalee Armstrong
• Press Releases

  NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

  November 14, 2024

   · 

  11 min read
• Press Releases

  Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

  November 14, 2024

   · 

  9 min read
• Press Releases

  Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

  November 14, 2024

   · 

  8 min read
• Press Releases

  Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis

  November 14, 2024

   · 

  4 min read
• Press Releases

  Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, for Treatment of Patients with Moderate to Severe Osteoarthritis at ACR Convergence 2024

  November 14, 2024

   · 

  3 min read
• Press Releases

  Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024

  November 14, 2024

   · 

  7 min read
• Press Releases

  Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study

  November 14, 2024

   · 

  13 min read
• Press Releases

  Sparrow Pharmaceuticals to Present Two Abstracts at ACR Convergence 2024 and Expand Phase 2 Clinical Trial of Clofutriben with Prednisolone for Polymyalgia Rheumatica to Fifth Cohort

  November 14, 2024

   · 

  2 min read